← Leaderboards
Jay L Rothstein
Thomas Jefferson University
$12,595,060
Attributed
$13,572,108
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2015–23$2.5M$1.9M$1.3M$625K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$13,572,108 · 6
By mechanism
R44$12,359,518 · 4
R42$954,097 · 1
P01$258,493 · 1
Top collaborators
- Christopher M Burns1 shared
- Randolph J. Noelle1 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Stephen P Peters$7,030,989
- Laurence Crane Eisenlohr$22,538,505
- Jay S Schneider$22,871,022
Others in their field
Top investigators on “Toxic Effect”
- George R Seage · Abt Associates, Inc.$224,114,540
- Peter C Adamson · National Childhood Cancer Foundation$126,756,857
- Gregory H Reaman · National Childhood Cancer Foundation$123,836,183
- Carol Nesel · Westat$116,355,411
- Mary M Horowitz · Medical College Of Wisconsin$90,165,506
- Barney Sparrow · Battelle Memorial Institute$88,494,220
Research focus
Toxic EffectPharmaceutical PreparationsClinicImmuneIn VivoLeadProgramsIn VitroNonhuman PrimateLaboratoriesAntibodiesImmunogenicityAutoimmune DiseasesCell LineAffinityMonoclonal AntibodiesEngineeringInflammatoryDisease ModelCellsNovel TherapeuticsClinical TrialsDoseImmune System
Grant awards (19)
Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases$993,646
R44 · FY2023 · AI · contact PI
Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases$112
R44 · FY2023 · AI · contact PI
Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases$974,853
R44 · FY2022 · AI · contact PI
Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases$990,946
R44 · FY2021 · AI · contact PI
Targeting leukocyte metabolism to treat human autoimmune disease$995,802
R44 · FY2020 · AI · contact PI
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$1,004,563
R44 · FY2019 · AI · contact PI
Targeting leukocyte metabolism to treat human autoimmune disease$996,128
R44 · FY2019 · AI · contact PI
Targeting leukocyte metabolism to treat human autoimmune disease$995,802
R44 · FY2018 · AI · contact PI
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$992,040
R44 · FY2018 · AI · contact PI
Targeting leukocyte metabolism to treat human autoimmune disease$299,502
R44 · FY2018 · AI · contact PI
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$991,804
R44 · FY2017 · AI · contact PI
Safe and effective anti CD154 antibodies for therapeutic intervention$912,191
R44 · FY2017 · AI · contact PI
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$299,938
R44 · FY2017 · AI · contact PI
Safe and effective anti CD154 antibodies for therapeutic intervention$912,191
R44 · FY2016 · AI · contact PI
Safe and effective anti CD154 antibodies for therapeutic intervention$1,000,000
R44 · FY2015 · AI · contact PI
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease$954,097
R42 · FY2015 · AI · contact PI
Role of Tcl-1 in Lymphoid Development$0
P01 · FY2002 · CA
Role of Tcl-1 in Lymphoid Development$0
P01 · FY2001 · CA
Role of Tcl-1 in Lymphoid Development$258,493
P01 · FY2000 · CA